BioHarvest Sciences (BHST) investor relations material

Technology and Product Innovation

• Achieved large-scale, scalable production of plant exosomes using proprietary bioreactor technology, enabling consistent, high-yield output of nanosized vesicles rich in bioactive compounds like viniferin.

• Exosomes are highly stable, homogenous, and offer superior bioavailability and efficacy for health, wellness, therapeutic, and cosmetic applications.

• Technology is cost-efficient, economically viable, and sets a new industry standard, providing a defensible advantage over conventional systems.

• Patent protection is in place for the exosome production process, with additional provisional applications planned.

• Bioreactors can be retrofitted with off-the-shelf equipment for exosome extraction, requiring no major new installations.

Commercialization and Market Opportunities

• Exosome technology enables direct-to-consumer products, B2B ingredient supply, and CDMO partnerships for cosmetics, pharma, and supplements.

• Immediate focus is on cosmetics, with potential to sign development contracts with global brands and CDMO customers as early as next quarter.

• Exosomes offer premiumization and high gross margins, especially in cosmetics, and can be integrated into both new and existing product lines.

• Pharmaceutical applications are advancing, with at least one FDA-approved drug project in the pipeline and more under negotiation.

• Exosomes are positioned as a safer, non-animal-derived alternative, with global market demand projected to grow significantly by 2030.

Strategic Initiatives and Growth Drivers

• Launching a blood flow hydration product targeting the $18 billion U.S. electrolyte drinks market, leveraging proprietary VINIA formulation.

• Product line includes multiple flavors, natural electrolytes, and is certified for use by professional athletes and military.

• HealthPros affiliate system is scaling rapidly, aiming to onboard 300+ professionals to drive product adoption and expand market reach.

• Direct-to-consumer business has generated over $60 million since 2021 with strong gross margins.

• Targeting adjusted EBITDA profitability in Q4, supported by new product launches, channel expansion, and innovation pipeline.